Revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
Adaptive Biotechnologies Corp (ADPT)
Price$24.28Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $277.0M | $179.0M | $170.3M | $185.3M | $154.3M | $98.4M | $85.1M | $55.7M | $38.4M |
| Gross profit | $205.6M | $106.9M | $94.7M | $127.4M | $105.0M | $75.9M | $62.8M | $36.0M | $22.8M |
| Gross margin | 74.24% | 59.72% | 55.63% | 68.75% | 68.06% | 77.10% | 73.82% | 64.67% | 59.22% |
| Research & development | $93.8M | $103.0M | $122.1M | $141.8M | $142.3M | $116.1M | $70.7M | $39.2M | $32.0M |
| Operating expenses | $334.1M | $341.5M | $397.3M | $385.5M | $363.3M | $251.2M | $163.5M | $105.4M | $82.9M |
| Operating income | −$57.1M | −$162.5M | −$227.0M | −$200.2M | −$209.0M | −$152.8M | −$78.4M | −$49.8M | −$44.5M |
| Operating margin | −20.62% | −90.83% | −133.33% | −108.03% | −135.39% | −155.33% | −92.15% | −89.39% | −115.68% |
| EBITDA | −$41.1M | −$145.1M | −$207.4M | −$179.3M | −$195.0M | −$144.3M | −$70.6M | −$43.8M | −$38.7M |
| EBITDA margin | −14.85% | −81.09% | −121.82% | −96.74% | −126.35% | −146.72% | −82.99% | −78.61% | −100.60% |
| Net income | −$59.5M | −$159.5M | −$225.3M | −$200.2M | −$207.3M | −$146.2M | −$68.6M | −$46.4M | −$42.8M |
| Net profit margin | −21.48% | −89.12% | −132.29% | −108.03% | −134.30% | −148.63% | −80.65% | −83.44% | −111.40% |
| Basic EPSper basic share | -$0.39 | -$1.08 | -$1.56 | -$1.40 | -$1.48 | -$1.11 | -$1.01 | -$3.67 | -$3.50 |
| Diluted EPSper diluted share | -$0.39 | -$1.08 | -$1.56 | -$1.40 | -$1.48 | -$1.11 | -$1.01 | -$3.67 | -$3.50 |
Owners
Reported shareholders
18.86%of listed shares
VIKING GLOBAL INVESTORS LP29.99M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
VIKING GLOBAL INVESTORS LP | 18.86%29.99M shares |
BlackRock, Inc. | 9.52%15.14M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.03%6.4M shares |
WELLINGTON MANAGEMENT GROUP LLP | 3.72%5.91M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.44%5.48M shares |
D. E. Shaw & Co., Inc. | 2.91%4.63M shares |
WESTFIELD CAPITAL MANAGEMENT CO LP | 2.68%4.27M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.29%3.64M shares |
STATE STREET CORP | 2.17%3.46M shares |
Invesco Ltd. | 1.95%3.09M shares |
GOLDMAN SACHS GROUP INC | 1.88%2.98M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 1.68%2.67M shares |
Driehaus Capital Management LLC | 1.59%2.53M shares |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.59%2.52M shares |
LORD, ABBETT & CO. LLC | 1.56%2.47M shares |
Nuveen, LLC | 1.49%2.37M shares |
BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1.37%2.18M shares |
ROBINS CHAD M | ≈1.37%2.18M shares |
FRED ALGER MANAGEMENT, LLC | 1.32%2.09M shares |
ARK Investment Management LLC | 1.31%2.09M shares |
Percentages use 159.06M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 · 10b5-1 | BENZENO SHARONChief Commercial Ofc Imm Med | SellCommon Stock | 154.8K | $21.14 | $3.27M | 221.3K |
| Jun 26, 2026Form 4 · 10b5-1 | BENZENO SHARONChief Commercial Ofc Imm Med | SellCommon Stock | 11.0K | $21.00 | $231.7K | 272.8K |
| Jun 25, 2026Form 4 · 10b5-1 | BOBULSKY SUSANChief Commercial Officer, MRD | SellCommon Stock | 5.0K | $20.50 | $102.5K | 406.8K |
| Jun 25, 2026Form 4 · 10b5-1 | GRIFFIN MICHELLE RENEEDirector | SellCommon Stock | 52.1K | $20.18 | $1.05M | 15.6K |
| Jun 16, 2026Form 4 · 10b5-1 | ROBINS HARLAN SChief Scientific Officer | SellCommon Stock | 6.2K | $18.01 | $110.9K | 1.41M |
Community posts
Adaptive reports broader NCCN guidance for residual-disease testing
Adaptive ($ADPT) Biotechnologies said updated National Comprehensive Cancer Network guidance for multiple myeloma gives measurable residual disease testing a dedicated section and names clonoSEQ as a testing option. The update specifies a p ...
